STAT+: Lilly says ‘triple-G’ drug beats Novo’s Ozempic in diabetes study
· statnews.com · popularity 32/100 · 0 similar stories today · Addiction & Behavioral Health (Health & Life Sciences)
Read the original at statnews.com →
Summary
Data add to expectations that the drug will be one of Lilly’s greatest growth drivers.
Found in: STAT News. Rating basis: single outlet; outlet tier 4; 1 feeds; feed position 6.